<DOC>
	<DOCNO>NCT02419391</DOCNO>
	<brief_summary>A total 63 subject recruit three group ( 18 subject per group receive MVA BN RSV vaccine three subject per group receive placebo ) . Liquid frozen suspension MVA BN RSV . Each subject receive two vaccination either MVA-BN RSV vaccine 1 x 108 TCID50 per 0.5 ml , 1 x 107 TCID50 per 0.5 ml placebo .</brief_summary>
	<brief_title>Trial Evaluate Safety , Tolerability Immunogenicity Recombinant MVA BN® RSV Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>sign date informed consent form Body mass index ≥ 18.5 &lt; 35 . Women childbearing potential ( WOCBP ) must use acceptable method contraception Pregnant breastfeeding woman . Uncontrolled serious infection , i.e . respond antimicrobial therapy . History serious medical condition . History active autoimmune disease . Known suspected impairment immunologic function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>RSV Vaccines</keyword>
	<keyword>Respiratory Syncytial Virus Vaccines</keyword>
</DOC>